Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2024

The inhibitory receptor CD300a functions as an immune checkpoint in a mouse model of breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMicha Ben‐ZimraSNShiran NiazovFAFidan Rahimly Alekberly

Discussion

Loading...

Member takes

Overview

Preclinical study demonstrates that CD300a deficiency reduces tumor burden and enhances mast cell activation in a breast cancer mouse model, suggesting CD300a acts as an immune checkpoint.

Key Points

  • CD300a deficiency suppresses tumor growth in a breast cancer mouse model, which coincides with heightened mast cell activation and loss of immunosuppressive IL-10 production.
  • Assessment using the 4T1 breast cancer mouse model shows that co-culture with CD300a-deficient mast cells reduces viable tumor cell counts compared to wild-type controls.
  • Highlights CD300a as a potential immune checkpoint target in breast cancer, though findings are derived from a mouse model and require further preclinical validation.

Cite This Study

Ben‐Zimra et al. (2024) studied this question.

synapsesocial.com/papers/68e6311cb6db6435875c32b0https://doi.org/10.21203/rs.3.rs-4488548/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD300a as a Potential Immune Checkpoint in Breast Cancer: Insights from in vivo and in vitro Models.2026
  2. 2Targeting CD300ld to normalize the tumor microenvironment: an emerging insight in cancer immunotherapy2024 · 3 citations
  3. 3Targeting CD276 for T cell-based immunotherapy of breast cancer2024 · 11 citations
  4. 4A regulatory B cell subpopulation expressing CD301b lectin promotes breast cancer growth2024
  5. 5Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation2024 · 7 citations